ORMP - ORAMED PHARMACEUTICALS INC.

2.03
-0.070   -3.448%

Share volume: 102,157
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$2.10
-0.07
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
7%
Profitability 0%
Dept financing 5%
Liquidity 50%
Performance 4%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.33%
1 Month
-19.12%
3 Months
-15.06%
6 Months
-15.42%
1 Year
-24.54%
2 Year
-5.58%
Key data
Stock price
$2.03
P/E Ratio 
0.00
DAY RANGE
$2.03 - $2.26
EPS 
$0.17
52 WEEK RANGE
$1.96 - $3.09
52 WEEK CHANGE
-$23.68
MARKET CAP 
97.555 M
YIELD 
N/A
SHARES OUTSTANDING 
40.769 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.01
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$98,296
AVERAGE 30 VOLUME 
$80,960
Company detail
CEO: Nadav Kidron
Region: US
Website: oramed.com
Employees: 10
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its flagship product is the ORMD-0801, an oral ingestible insulin capsule. It is also developing an oral glucagon-like peptide-1 capsule.

Recent news
loading